CA-BEHAVIOSEC
31.5.2019 15:02:03 CEST | Business Wire | Press release
BehavioSec, the first vendor to pioneer behavioral biometrics, is attending Money20/20 Europe on June 3-5, 2019 in Amsterdam, Netherlands at the Amsterdam RAI. Money20/20 focuses on the mission of creating a simpler, fairer, faster and more inclusive financial system for individuals, businesses and society as a whole, bringing together more than 350 speakers to deliver the next frontier of Financial Services. BehavioSec CEO Neil Costigan will join the panel discussion, “The Changing Nature of Attacks and Attackers,” where he will discuss cybersecurity and risk management in an age where online commerce and trust are threatened by cybercrime threats continually bypassing traditional password authentication and anti-fraud measures.
Money20/20 attendees can visit BehavioSec at booth H92 throughout the event. BehavioSec will meet with customers and industry partners, brief media and analysts and present demos of the company’s Behavioral Biometrics Software Platform . Already in use with some of the biggest global brands in FinTech and financial services, BehavioSec’s software provides continuous online authentication of account holders by analyzing their unique physical behaviors, like typing patterns, cursor movements and touchscreen inputs.
“Traditional, one-time authentication measures like thumbprints and passwords can no longer protect and enable digital transformation in the financial services sector,” said Costigan. “With today’s constantly evolving attacks bypassing even once reliable multi-factor authentication methods, financial service organizations must find new ways to prevent fraud and cyber attacks without slowing down usability and functionality. Presenting at Money20/20 gives us the opportunity to show the success of behavioral biometrics in combating account takeover fraud in this new threat landscape.”
Join BehavioSec’s Neil Costigan at the following session:
|
What: |
The Changing Nature of Attacks and Attackers |
|
|
Who: |
Neil Costigan, CEO, BehavioSec (Speaker) | |
| Dr. Yinglian Xie, Co-Founder and CEO, DataVisor (Speaker) | ||
| Max Laemmle, Founder and CEO, Fraugster Limited (Speaker) | ||
| Andrew Jamieson, Technology & Security Director, UL (Moderator) | ||
|
When: |
Wednesday, June 5, 2019 from 14:10 p.m. to 14:50 p.m. CEST | |
|
Where: |
Industry Transmutation Stage at RAI Amsterdam, Amsterdam, Netherlands |
As CEO of BehavioSec, Costigan leads the company’s work delivering innovative behavioral biometric technology protecting consumer transactions, payments and financial firms from fraud and theft. He has more than 25 years’ of entrepreneurial and technical leadership experience in venture-backed startups, and global technology corporations spanning the U.S., and EU. A cryptographer by training, his career expanded to include software development, executive leadership and entrepreneurship. He holds an extensive portfolio of patents and serves as Principal Investigator for BehavioSec’s U.S. DOD DARPA projects.
Prior to BehavioSec, Costigan was VP for R&D at Smart Card manufacturer Gemplus (now Gemalto) and Co-founder/CTO at PKI specialists Celo Communications (Celo). Neil holds a PhD (2009) for his thesis on Elliptic Curve Cryptography on Modern Processor Architectures and has developed a number of commercial security applications. He frequently presents and presents on innovation, cryptography and network security.
Follow BehavioSec for more details and the latest in behavioral biometrics technology:
About BehavioSec
BehavioSec is the first vendor to pioneer behavioral biometrics. The company’s Behavioral Biometrics Platform is widely deployed across Global 2000 companies for its proven ability to dramatically reduce account fraud and data theft. Founded in 2008 out of groundbreaking academic research, BehavioSec technology allows companies to continuously verify digital identities with superior precision, in real-time. Strengthened with the leadership of serial entrepreneurs and experienced industry professionals, the BehavioSec team now spans the world, providing security while preserving a rich digital experience throughout web and mobile apps. BehavioSec is the only enterprise-grade vendor used in global deployments with some of the largest companies, reducing manual review whilst safeguarding millions of users and billions of transactions. BehavioSec investors include Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures and Octopus Ventures. BehavioSec is headquartered in San Francisco, CA and has global operations throughout Europe and Asia Pac. For more information, visit www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190531005032/en/
Contact:
Media Contact: Savannah Young +1 (703) 877-8111 pr@behaviosec.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom